1. Introduction {#sec1}
===============

Acute aortic dissection (AAD) is a rare, life-threatening condition associated with high morbidity and mortality rates \[[@B1], [@B2]\]. In-hospital mortality rates of patients with AAD is up to 27.4% \[[@B2], [@B3]\], with type B AAD reported to account for one-third of all AAD cases \[[@B4]\]. Despite the recent improvements in management of type B AAD, mortality rates and postoperative complications of this disease remain high \[[@B5]\]. Studies have reported that medical treatment has been accepted as standard management for type B AAD, although its 5-year total survival rate stands at 60% \[[@B6]\]. It is, therefore, urgent to investigate the risk factors of type B AAD mortality and develop an effective intervention. Studies have reported several risk factors for type B AAD in-hospital mortality, including age, hypertension, ischemic complications, and genetic factors \[[@B7]\].

To date, dyslipidemia is a well-documented risk factor for stroke \[[@B8], [@B9]\], metabolic syndrome \[[@B10]\], and cardiovascular disease \[[@B11], [@B12]\]. Moreover, results from a meta-analysis suggested that lipid-modifying therapy is a protective factor on mortality after abdominal aortic aneurysm repair \[[@B13]\]. A cross-sectional study implicated dyslipidemia aortic stiffness \[[@B14]\], with international guidelines stating that lipid profiles should be managed \[[@B15]\]. Atherogenic dyslipidemia, a combination of low high-density lipoprotein cholesterol (HDL-c) and high triglyceride (TG) with elevated small dense low-density lipoprotein (LDL) particles and apolipoprotein B, is an important part of the metabolic syndrome and a powerful predictor of cardiovascular disease \[[@B16]--[@B18]\]. However, the costs of performing the LDL phenotyping are expensive and have not been standardized \[[@B19], [@B20]\]. As a possible alternative, the TG/HDL-c ratio has been considered an easily available atherosclerotic marker \[[@B21]\]. Previous studies have reported that a higher TG/HDL-C ratio is related with LDL phenotype B, small insulin resistance, HDL particles, and cerebro/cardiovascular diseases \[[@B16]\]. In the current study, we aimed to evaluate the relationship between TG/HDL-c ratio and in-hospital mortality in patients with type B AAD.

2. Methods {#sec2}
==========

2.1. Participants {#sec2.1}
-----------------

This was a retrospective study, in which we nonselectively and consecutively evaluated 1526 patients between January 2015 and December 2018 at the Second Xiangya Hospital of Central South University. The Diagnostic process was mainly based on guidelines proposed by ESC 2014 on the treatment and diagnosis of aortic diseases \[[@B22]\]. Among the patients, 140 of them who showed presence of symptoms for more than 14 days were excluded. Similarly, those whose covariate data was missing (uncompleted serum triglyceride or high-density lipoprotein cholesterol tests) were also excluded. According to the Stanford classification, which is based on anatomical categorization \[[@B23]\], a total of 564 type A AAD patients were excluded. Finally, 523 type B AAD patients were enrolled in the study ([Figure 1](#fig1){ref-type="fig"}). The study was approved by the Institutional Review Board at the Second Xiangya Hospital of Central South University.

2.2. Clinical Assessment {#sec2.2}
------------------------

We evaluated risk factors and demographic characteristic, including age, gender, body mass index (BMI), hypertension, stroke, smoking, diabetes milieus (DM), atherosclerosis, Marfan syndrome (MFS), chronic renal insufficiency (CRI), systolic blood pressure (SBP), diastolic blood pressure (DBP), operation, and mortality. Laboratory examinations including white blood cells count (WBC), hemoglobin (Hb), high-density lipoprotein cholesterol (HDL-c), platelet count (PLT), serum triglyceride (TG), alanine transaminase (ALT), uric acid (UA), creatinine (Cr), aspartate aminotransferase (AST), and troponin T (TnT) were analyzed in blood collection from AAD patients in the morning, following 12 hours of fasting. A TG/HDL-c ratio was calculated after by dividing TG levels by HDL cholesterol levels.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Continuous variables were expressed as mean ± standard deviations of the mean (normal distribution) or median with interquartile range (IQR) (Skewed distribution), while categorical variables were expressed as frequencies or percentages. Kruskal-Wallis H (skewed distribution) and One-Way ANOVA tests (normal distribution) or *χ*^2^ (categorical variables) were performed, applied, and compared with Q1, Q2, Q3, and Q4 (TG/HDL-c ratio categorized as quartiles). To investigate the relationship between TG/HDL-c ratios and in-hospital mortality, we performed statistical analyses based on 3 points. First, we use univariate and multivariate linear regression model analyses. A total of three models were established: model I, in which only sociodemographic data were adjusted; model II, the model I added other covariates shown in [Table 1](#tab1){ref-type="table"}. Secondly, in order to solve the nonlinearity of TG/HDL-c ratio and in-hospital mortality, a smooth curve fitting (penalized spline method) was conducted. If nonlinearity was detected, we first calculated the inflection point using the recursive algorithm and then constructed a two-piecewise linear regression on both sides of the inflection point. This was followed by determination of the best fit model on the basis of *P* values for log-likelihood ratio test. The third step involved subgroup analysis based on stratified linear regression models. Continuous variables were initially transformed into categorical variables using the clinical quartile of cut point, followed by interaction tests. Tests for effect modification across subgroup indicators were followed by analysis of likelihood ratios. Sensitivity analyses were then performed, in which the TG/HDL-c ratio was converted to categorical variables for calculation of the *P* for trend to ensure the robustness of the analysis. The aim of this step was to validate the results of TG/HDL-c ratio as continuous variables and to detect nonlinearity. These analyses were carried out in Empower Stats (<http://www.empowerstats.com>, X&Y Solutions Inc., Boston, MA) \[[@B24]\] and R (<http://www.r-projec.org>, The R Foundation). Statistical significance was determined at *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Baseline Characteristics and Univariate Analyses {#sec3.1}
-----------------------------------------------------

A total of 523 type B AAD patients were enrolled in the study, and this resulted a median age of 55.00 ± 11.74 years. 84.32% of these were male. A flow chart outlining their selection is presented in [Figure 1](#fig1){ref-type="fig"}, while baseline features of the enrolled patients are outlined in [Table 1](#tab1){ref-type="table"}. In-hospital mortality was found in 33 (6.31%) patients. Univariate analyses indicated that the outcome variable was associated with CRI, operation, and the levels of Hb, AST, ALT, TG, TG/HDL-c ratio, Cr, UA, and TnT ([Table 2](#tab2){ref-type="table"}).

3.2. TG/HDL-c Ratio Increased the In-Hospital Mortality {#sec3.2}
-------------------------------------------------------

Results from the Kaplan-Meier analysis showed a significantly higher cumulative in-hospital survival rate in the Q1 relative to the other groups (log-rank *χ*^2^ = 12.96, *P* = 0.005) ([Figure 2](#fig2){ref-type="fig"}).

3.3. The Relationship between TG/HDL-C Ratio and In-Hospital Mortality {#sec3.3}
----------------------------------------------------------------------

We established three models in order to examine the independent effects of TG/HDL-c ratio on in-hospital mortality after adjusting for confounding factors ([Table 3](#tab3){ref-type="table"}). Model III resulted in a TG/HDL-c ratio (OR = 2.08, 95% CI = 1.32 to 3.27, *P* = 0.002) remained an important predictor of in-hospital mortality after all adjusted covariates are showed in [Table 1](#tab1){ref-type="table"}. We also converted TG/HDL-c ratio from continuous to categorical variable (quartiles), the *P* for the trend of categorized TG/HDL-c ratio in the fully adjusted model matched with the result when TG/HDL-c ratio is a continuous variable. However, when the TG/HDL-c ratio enters the fully-adjusted model as a categorical variable, the trend of the effective value in the different TG/HDL-c ratio group had nonequidistant changes. There may be a nonlinear relationship between TG/HDL-c ratio and in-hospital mortality according to this kind of nonequidistant changes in effect size.

3.4. The Nonlinearity of TG/HDL-c Ratio and In-Hospital Mortality {#sec3.4}
-----------------------------------------------------------------

We performed further analysis on the nonlinear relationship of TG/HDL-c ratio with in-hospital mortality ([Table 4](#tab4){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}). Results of the smooth curve indicated nonlinear relationship (adjusted for other covariates listed in [Table 1](#tab1){ref-type="table"}) between TG/HDL-c ratio and in-hospital mortality. We used the two-piecewise linear regression and the linear regression models to fit the association between TG/HDL-c ratio and in-hospital mortality, respectively. The *P* value for the log-likelihood ratio test was 0.017, indicating that the two-side linear regression was more appropriate for fitting the association between TG/HDL-c ratio and in-hospital mortality because it can accurately represent the relationship between them. The inflection point, determined by the two-piecewise recursive algorithm and linear regression, was 2.05. On the left side of the inflection point (TG/HDL − c ratio ≤ 2.05), the effect size and 95% CI were 3.17, 1.54 to 6.57, respectively. On the right side of the inflection point (TG/HDL − c ratio \> 2.05), the relationship cannot be observed (1.003 (95% CI 0.8-1.26), *P* = 0.983). Though they are all consistent with an increased risk of in-hospital mortality in the right side of the inflection point, there is a lack of a statistically significant association with the TG/HDL-c ratio.

3.5. Subgroup Analysis {#sec3.5}
----------------------

In the subgroup analysis, we used the stratification variables, including gender, BMI, DM, age, smoking, hypertension, atherosclerosis, CRI, stroke, WBC, PLT, Hb, ALT, AST, Cr, UA, UA, and operation, to observe the trend of effect sizes ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

The current study resulted in three main findings. First, we found a positive relationship between TG/HDL-c ratio and in-hospital mortality, after adjusting other covariates. This indicated that an increase in TG/HDL-c ratio produces 2.08-fold increase in in-hospital mortality. Secondly, our analysis revealed nonlinearity between in-hospital mortality and TG/HDL-c ratio. Given that this correlation displayed a ratio-response pattern, our findings may provide clues for the potential pathophysiologic mechanisms. Thirdly, our results confirmed an association between in-hospital mortality and TG/HDL-C ratio in type B AAD in Chinese patients which can be used to screen high-risk individuals. To better understand the trend in this association in different populations, we performed subgroup analysis and found stable results.

Several studies have suggested high levels of TG/HDL-c ratio in cardiovascular diseases across Europe and Asian Pacific populations \[[@B25]--[@B27]\]. TG/HDL-c ratio indicates harmful small/dense LDL particles and has been found to have a positive association with atherosclerosis \[[@B28]\]. Moreover, a previous study \[[@B14]\] analyzing lipid parameters of 603 participants to evaluate aortic stiffness found a significant association between aortic stiffness with total cholesterol/HDL, total cholesterol, and non-HDL. Therefore, the cholesterol deposition in the aortic tissues may explain the development of type B AAD or abdominal aortic aneurysm. In additional, there is a large number of evidence that has suggested the role of TG/HDL-c ratio in prediction of poor outcomes in cardiovascular, especially myocardial infarction and ischemic stroke \[[@B28], [@B29]\]. Furthermore, previous studies have also deduced that the TG/HDL-c ratio has a positive association with the occurrence of ischemic \[[@B30]\], which is potentially the source of high TG/HDL-c ratio in type B AAD patients \[[@B31]\].

Although operation is still the most effective way to avoid in-hospital deaths in patients with AAD, other risk factors for the prediction of in-hospital mortality need to be considered. Our results suggested that TG/HDL-c ratio is one of the risk factors for in-hospital mortality. Clinical therapies should therefore arouse high attention to the ratio with these patients. Increased TG/HDL-c ratios are not only related to aortic stiffness, but also an indicator of inflammatory factors and oxidative stress, which show a risk of type B AAD and a poor prognosis. Recent evidence suggests that inflammatory factors and oxidative stress play a crucial role in the pathogenesis and progression of AAD \[[@B32], [@B33]\]. For instance, Daiber et al. \[[@B34]\] reported the quality of high-density lipoprotein changes under oxidative stress conditions. Similarly, Kaye et al. \[[@B35]\] found that if the levels of HDL are insufficient, cholesterol and lipids in arterial walls trigger an exacerbated inflammatory response. Meta-analysis reported that low serum lipids may reduce patient mortality after abdominal aortic aneurysm repair \[[@B13]\]. Overall, increased TG/HDL-c ratio in type B AAD is associated with aortic stiffness, inflammatory factors, and oxidative stress.

The advantages of our research are strict statistical adjustment, subgroup analysis, and large research population. However, there are some weaknesses in the study. Firstly, the participants herein were mainly Chinese AAD patients, recruited in central south China. As a result of this sampling, our study may not be generalizable to AAD populations in other regions as factors influencing cholesterol levels may vary. Secondly, we excluded chronic AD and type A AAD patients from analysis; therefore, the study conclusion does not apply to these people. Consequently, because it is a retrospective study, some variables such as physical activity, diet, and daily habits were not achieved. We also were not able to know if the patients had fibrates. Nevertheless, our study results indicate that the TG/HDL-C ratio is a risk factor. If a patient takes lipid-lowering drugs, high TG/HDL-C ratio will have a strong positive association with in-hospital mortality.

5. Conclusions {#sec5}
==============

The TG/HDL-c ratio and in-hospital mortality in type B AAD have a nonlinear relationship among Chinese population. This ratio increased in-hospital mortality when it is less than 2.05.
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![Flow chart of patient enrollment.](BMRI2020-5419846.001){#fig1}

![Kaplan-Meier curves for in-hospital survival according to TG/HDL-c (quartiles) in all type B AAD patients.](BMRI2020-5419846.002){#fig2}

![Association between TG/HDL-c ratio and in-hospital mortality. A nonlinear association between TG/HDL-c ratio and in-hospital mortality was found. The solid red line represents the smooth curve fit between variables. Blue bands represent the 95% confidence interval from the fit. All adjusted for gender, age, BMI, hypertension, smoking, atherosclerosis, WBC, PLT, Hb, ALT, AST, Cr, UA, and TnT.](BMRI2020-5419846.003){#fig3}

###### 

Baseline characteristics of the cohort (*N* = 523).

  Characteristics   Total                  TG/HDL-c ratio (mmol/L) (quartiles)   *P* value                                                            
  ----------------- ---------------------- ------------------------------------- ---------------------- ---------------------- ---------------------- ---------
  *n*               523                    131                                   130                    131                    131                    
  Age (years)       55.00 ± 11.74          57.71 ± 10.46                         55.95 ± 12.05          52.54 ± 10.96          53.80 ± 12.81          \<0.001
  Female            82 (15.68%)            29 (22.14%)                           25 (19.23%)            17 (12.98%)            11 (8.40%)             0.010
  BMI (kg/cm^2^)    25.47 ± 3.87           24.65 ± 3.10                          24.63 ± 4.25           26.91 ± 4.74           25.72 ± 2.80           0.291
  SBP               150.73 ± 27.17         155.54 ± 27.35                        149.07 ± 26.46         149.57 ± 26.10         148.67 ± 28.47         0.134
  DBP               86.02 ± 16.18          87.56 ± 15.81                         84.29 ± 14.85          87.06 ± 17.53          85.16 ± 16.37          0.312
  Smoking           209 (39.96%)           42 (32.06%)                           46 (35.38%)            53 (40.46%)            68 (51.91%)            0.006
  DM                25 (4.78%)             9 (6.87%)                             2 (1.54%)              11 (8.40%)             3 (2.29%)              0.020
  Hypertension      386 (73.80%)           85 (64.89%)                           90 (69.23%)            99 (75.57%)            112 (85.50%)           \<0.001
  Stroke            16 (3.06%)             8 (6.11%)                             2 (1.54%)              4 (3.05%)              2 (1.53%)              0.104
  Atherosclerosis   51 (9.75%)             11 (8.40%)                            10 (7.69%)             12 (9.16%)             18 (13.74%)            0.345
  MFS               5 (0.96%)              1 (0.77%)                             1 (0.77%)              2 (1.53%)              1 (0.77%)              0.529
  CRI               16 (3.06%)             1 (0.76%)                             4 (3.08%)              7 (5.34%)              4 (3.05%)              0.201
  WBC (×109/L)      10.92 ± 3.76           10.89 ± 3.23                          11.41 ± 4.33           10.52 ± 3.49           10.88 ± 3.88           0.401
  PLT (×109/L)      195.77 ± 78.14         165.81 ± 55.25                        190.14 ± 61.16         210.46 ± 89.90         216.62 ± 89.90         \<0.001
  Hb (g/L)          125.76 ± 20.60         126.84 ± 17.68                        125.72 ± 21.36         125.63 ± 21.86         124.82 ± 21.43         0.923
  ALT (u/L)         19.95 (13.50-33.38)    16.60 (11.45-24.55)                   18.50 (13.03-28.70)    23.30 (14.33-34.92)    25.80 (16.10-51.30)    \<0.001
  AST (u/L)         19.50 (15.15-28.60)    20.10 (15.75-26.15)                   18.20 (14.85-25.00)    18.85 (14.85-26.28)    22.45 (15.30-37.80)    0.121
  Cr (umol/L)       79.10 (65.45-103.88)   72.30 (59.90-88.20)                   74.70 (63.30-102.20)   76.20 (63.40-104.05)   92.50 (73.50-122.20)   \<0.001
  UA (mmol/L)       317.49 ± 111.70        300.27 ± 105.43                       332.41 ± 118.87        310.98 ± 103.98        326.31 ± 116.19        0.031
  TnT (pg/mL)       7.83 (4.50-14.02)      7.17 (4.59-9.68)                      7.46 (4.83-11.98)      6.99 (3.66-13.57)      9.87 (5.53-21.50)      0.001
  TG (mmol/L)       1.48 ± 0.85            0.71 ± 0.19                           1.06 ± 0.22            1.53 ± 0.43            2.63 ± 0.72            \<0.001
  HDL-c (mmol/L)    1.19 ± 0.32            1.46 ± 0.33                           1.20 ± 0.22            1.06 ± 0.26            1.03 ± 0.26            \<0.001
  Operation                                                                                                                                           0.003
   No               117 (22.37%)           37 (28.24%)                           14 (10.77%)            32 (24.43%)            34 (25.95%)            
   Yes              406 (77.63%)           94 (71.76%)                           116 (89.23%)           99 (75.57%)            97 (74.05%)            
  Mortality                                                                                                                                           \<0.001
   Survivor         490 (93.69%)           129 (98.47%)                          126 (96.92%)           121 (92.37%)           114 (87.02%)           
   Nonsurvivor      33 (6.31%)             2 (1.53%)                             4 (3.08%)              10 (7.63%)             17 (12.98%)            

Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastole blood pressure; WBC: white blood cells count; PLT: platelet count; Hb: hemoglobin; ALT: alanine transaminase; AST: aspartate aminotransferase; Cr: creatinine; UA: uric acid; TnT: troponin T; DM: diabetes mellitus; MFS: Marfan syndrome; CRI: chronic renal insufficiency; TG: triglyceride; HDL-c: high-density lipoprotein cholesterol.

###### 

Univariate analysis for in-hospital mortality.

  Characteristics   Statistics             OR (95% CI)          *P* value
  ----------------- ---------------------- -------------------- -----------
  Age (years)       55.00 ± 11.74          1.01 (0.99, 1.04)    0.366
  Female            82 (15.68%)            0.33 (0.08, 1.41)    0.135
  BMI               25.47 ± 3.87           1.00 (0.89, 1.15)    0.673
  SBP               150.73 ± 27.17         0.99 (0.98, 1.01)    0.352
  DBP               86.02 ± 16.18          0.99 (0.97, 1.01)    0.479
  Smoking           209 (39.96%)           1.45 (0.71, 2.94)    0.304
  Diabetes          25 (4.78%)             0.61 (0.08, 4.63)    0.629
  Hypertension      386 (73.80%)           1.34 (0.57, 3.16)    0.502
  Stroke            16 (3.06%)             1.45 (0.71, 2.94)    0.304
  Atherosclerosis   51 (9.75%)             0.92(0.04, 2.06)     0.895
  MFS               5 (0.96%)              3.80 (0.41, 34.97)   0.239
  CRI               16 (3.06%)             7.78 (2.53, 23.92)   0.001
  WBC (×109/L)      10.92 ± 3.76           1.00 (0.93, 1.05)    0.980
  PLT (×109/L)      195.77 ± 78.14         1.00 (0.97, 1.03)    0.153
  Hb (g/L)          125.76 ± 20.60         0.97 (0.95, 0.98)    \<0.001
  ALT (u/L)         19.95 (13.50-33.38)    1.00 (1.00, 1.00)    0.032
  AST (u/L)         19.50 (15.15-28.60)    1.00 (1.00, 1.00)    \<0.001
  Cr (umol/L)       79.10 (65.45-103.88)   1.00 (1.00, 1.00)    0.005
  UA (mmol/L)       317.49 ± 111.70        1.00 (1.00, 1.00)    0.005
  TnT (pg/mL)       7.83 (4.50-14.02)      1.00 (1.00, 1.00)    0.002
  TG (mmol/L)       1.48 ± 0.85            2.01 (1.41, 2.86)    \<0.001
  HDL-c (mmol/L)    1.19 ± 0.32            0.46 (0.14, 1.53)    0.202
  TG/HDL-c ratio    1.37 ± 0.89            2.04 (1.40, 2.97)    \<0.001
  Operation                                                     \<0.001
   No               117 (22.37%)           Ref                  
   Yes              406 (77.63%)           0.04 (0.02, 0.09)    

Abbreviations: CI: confidence interval; OR: odds ratio; BMI: body mass index; SBP: systolic blood pressure; DBP: diastole blood pressure; WBC: white blood cells count; PLT: platelet count; Hb: hemoglobin; ALT: alanine transaminase; AST: aspartate aminotransferase; Cr: creatinine; UA: uric acid; TnT: troponin T; DM: diabetes mellitus; MFS: Marfan syndrome; CRI: chronic renal insufficiency; TG: triglyceride; HDL-c: high-density lipoprotein cholesterol.

###### 

Relationship between TG/HDL-c ratio and in-hospital mortality in different models.

  Exposure         OR (95% CI), *P* value                                   
  ---------------- ---------------------------- --------------------------- ---------------------------
  TG/HDL-c ratio   2.04 (1.40, 2.97), \<0.001   2.03 (1.39, 2.95), 0.0002   2.08 (1.32, 3.27), 0.002
  TG/HDL-c ratio                                                            
   Q1              Ref                          Ref                         Ref
   Q2              1.15 (0.29, 4.58), 0.847     1.17 (0.29, 4.68), 0.824    2.56 (0.55, 11.96), 0.231
   Q3              3.77 (1.27, 11.12), 0.017    3.90 (1.31, 11.66), 0.015   4.57 (1.28, 16.37), 0.020
   Q4              4.18 (1.43, 12.25), 0.009    3.95 (1.34, 11.61), 0.013   5.29 (1.50, 18.70), 0.010
  *P* for trend    \<0.0001                     \<0.0001                    \<0.0001

Abbreviations: CI: confidence interval; OR: odds ratio; TG/HDL-c: triglyceride/high-density lipoprotein cholesterol. Crude model adjusted for none. Model I adjusted for gender, BMI, and age. Model II adjusted for gender, age, BMI, hypertension, smoking, atherosclerosis, WBC, PLT, Hb, ALT, AST, Cr, UA, and TnT.

###### 

The results of the two-piecewise linear model.

                                                     *N* (%)       OR (95% CI)         *P* value
  -------------------------------------------------- ------------- ------------------- -----------
  Fitting model by standard linear regression        523(100%)     2.08 (1.32, 3.27)   0.002
  Fitting model by two-piecewise linear regression                                      
   The inflection point of TG/HDL-c ratio                                               
    ≤2.05                                            421 (80.5%)   3.17 (1.54, 6.57)   0.001
    \>2.05                                           102 (19.5%)   1.00 (0.80, 1.26)   0.983
  *P* for the log-likelihood ratio test              0.017                             

Abbreviations: CI: confidence interval; OR: odds ratio. Adjusted for gender, age, BMI, hypertension, smoking, atherosclerosis, WBC, PLT, Hb, ALT, AST, Cr, UA, and TnT.

###### 

Results of subgroup analysis and interaction analysis.

  Characteristic    No.   OR (95% CI)          *P* for interaction
  ----------------- ----- -------------------- ---------------------
  Age (years)                                  0.808
   \<50             169   1.60 (0.73, 3.53)    
   50-60            163   2.01 (1.21, 3.35)    
   \>60             191   1.63 (1.00, 2.63)    
  Gender                                       0.706
   Male             441   1.66 (1.18, 2.33)    
   Female           82    2.10 (0.67, 6.57)    
  BMI (kg/m^2^)                                0.448
   \<23             214   1.51 (0.32, 7.12)    
   23-26.5          216   3.69 (1.01, 13.40)   
   \>26.5           215   6.67 (0.91, 48.89)   
  Smoking                                      0.039
   No               314   2.36 (1.51, 3.68)    
   Yes              209   1.18 (0.72, 1.95)    
  DM                                           0.271
   No               498   1.82 (1.31, 2.53)    
   Yes              25    0.53 (0.04, 7.96)    
  Hypertension                                 0.217
   No               137   1.08 (0.44, 2.70)    
   Yes              386   1.90 (1.32, 2.74)    
  Stroke                                       0.635
   No               507   1.70 (1.22, 2.35)    
   Yes              16    1.37 (0.59, 3.19)    
  Atherosclerosis                              0.749
   No               472   1.70 (1.22, 2.36)    
   Yes              51    2.20 (0.49, 9.80)    
  CRI                                          0.389
   No               507   1.60 (1.13, 2.27)    
   Yes              16    1.22 (0.90, 1.65)    
  WBC (×10^9^/L)                               0.057
   \<9              173   1.26 (0.75, 2.10)    
   9-12             175   3.33 (1.71, 6.50)    
   \>12             174   1.54 (0.80, 2.98)    
  PLT (×10^9^/L)                               0.875
   \<160            174   1.94 (1.16, 3.25)    
   160-210          171   1.59 (0.84, 3.00)    
   \>210            178   1.91 (1.06, 3.45)    
  Hb (g/L)                                     0.406
   \<120            168   1.57 (1.05, 2.35)    
   120-135          175   1.19 (0.46, 3.08)    
   \>135            180   2.55 (1.19, 5.43)    
  ALT (u/L)                                    0.663
   \<15             173   2.17 (1.25, 3.78)    
   15-25            172   1.43 (0.68, 3.02)    
   \>25             173   1.77 (1.01, 3.11)    
  AST (u/L)                                    0.571
   \<15             171   2.15 (1.16, 3.98)    
   15-25            172   1.99 (1.12, 3.54)    
   \>25             176   1.41 (0.78, 2.54)    
  Cr (umol/L)                                  0.801
   \<70             172   1.99 (0.69, 5.72)    
   70-92            174   1.31 (0.62, 2.76)    
   \>92             174   1.62 (1.06, 2.46)    
  UA (mmol/L)                                  0.618
   \<5              173   2.29 (1.08, 4.84)    
   5-7              172   1.43 (0.80, 2.54)    
   \>7              173   1.72 (1.05, 2.83)    
  Operation                                    0.020
   No               117   2.73 (1.58, 4.71)    
   Yes              406   1.04 (0.52, 2.10)    

Abbreviations: CI: confidence interval; OR: odds ratio; BMI: body mass index; WBC: white blood cells count; PLT: platelet count; Hb: hemoglobin; ALT: alanine transaminase; AST: aspartate aminotransferase; Cr: creatinine; UA: uric acid; DM: diabetes mellitus; MFS: Marfan syndrome; CRI: chronic renal insufficiency; TG/HDL-c ratio: triglyceride/high-density lipoprotein cholesterol ratio.
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